EUVIMEDEUVIMED entdecken
Open Access

Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma

Maen Abdelrahim iD, Alejandro Mejia, Abdullah Esmail iD, Juan Carlos Barrera Gutierrez, Mahmoud Ouf iD, Joseph W Franses iD, Irun Bhan iD, Sudha Kodali, Ashish Saharia iD, Amit Mahipal iD, Nikolas Naleid iD, Catherine Bridges iD und 10 weitere

JCO Precision Oncology · 2025-07 · (9)

DOI: 10.1200/po-24-00934 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-07. Verfasst von Maen Abdelrahim und 21 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). We evaluated the utility of circulating tumor DNA (ctDNA) to predict relapse/progression risk in patients with HCC. Materials and Methods This retrospective analysis examined real-world data from ctDNA testing on 125 patients with HCC (721 plasma samples) undergoing curative-intent treatments and SOC management. Patients were divided into four subcohorts: cohort A (n = 64) and B (n = 52) comprised patients under recurrence monitoring after LT or resection, respectively. Cohort C (n = 4) and D (n = 5) comprised patients under treatment response monitoring with known recurrence or inoperable disease, respectively. A personalized, tumor-informed 16-plex polymerase chain reaction next-generation sequencing assay (Signatera, Natera, Inc, Austin, TX) was used for ctDNA testing. The molecular residual disease (MRD) window was defined as 2-12 weeks post-LT/resection (cohorts A/B), before starting adjuvant therapy (AT). Surveillance window was defined as post-MRD window or 2 weeks post-AT (cohort B) or during ongoing treatment (cohorts C/D). RESULTS The median follow-up was 40 (1.5-60) months. In cohort A, 97.2% (35/36) of patients with ctDNA negativity in the MRD window remained negative during surveillance. In cohort B, ctDNA was detected in 29.4% (10/34) of patients within the MRD window, all of whom experienced clinical recurrence (hazard ratio [HR], 7.2 [95% CI, 2.6 to 20]; P < .0001). In the surveillance window (cohort B), the ctDNA detection rate was 32.3% (10/31), and all experienced recurrence (HR, 18.0 [95% CI, 3.9 to 85]; P < .0001). In cohorts C/D, on-treatment ctDNA dynamics were concordant with treatment response as measured by imaging. Compared with alpha-fetoprotein, ctDNA had higher sensitivity and a significantly longer lead time (7.9 v 2.2 months) for recurrence detection. CONCLUSION Serial ctDNA testing effectively identified HCC recurrence early, postresection and post-LT. ctDNA was also useful for treatment response monitoring and could help resolve ambiguous imaging results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCirculating Tumor DNANeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedRetrospective StudiesAgedFeasibility StudiesPrecision MedicineAdultEarly Detection of Cancer

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX.
  • The Liver Institute at Methodist Dallas Medical Center, Dallas, TX.
  • Georgetown University Medical Center, Washington, DC.
  • The University of Chicago, Chicago, IL.
  • Massachusetts General Hospital, Boston, MA.
  • JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston, TX.

ORCID-Profile: Maen Abdelrahim, Abdullah Esmail, Mahmoud Ouf, Joseph W Franses, Irun Bhan, Ashish Saharia, Amit Mahipal, Nikolas Naleid, Catherine Bridges, Vasily N Aushev, Arkarachai Fungtammasan, J Bryce Ortiz, Adham Jurdi, Minetta C Liu, Aiwu Ruth He

Förderung

  • NCI NIH HHS

Zitieren

APA

Abdelrahim, M., Mejia, A., Esmail, A., Barrera Gutierrez, J. C., Ouf, M., Franses, J. W., Bhan, I., Kodali, S., Saharia, A., Mahipal, A., Naleid, N., Bridges, C., Tin, A., Brewer, C. M., Aushev, V. N., Fungtammasan, A., Palsuledesai, C. C., Ortiz, J. B., Jurdi, A., …, & He, A. R. (2025). Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00934

Vancouver

Abdelrahim M, Mejia A, Esmail A, Barrera Gutierrez JC, Ouf M, Franses JW, et al. Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00934

BibTeX
@article{Abdelrahim2025,
  author = {Abdelrahim, Maen and Mejia, Alejandro and Esmail, Abdullah and Barrera Gutierrez, Juan Carlos and Ouf, Mahmoud and Franses, Joseph W and Bhan, Irun and Kodali, Sudha and Saharia, Ashish and Mahipal, Amit and Naleid, Nikolas and Bridges, Catherine and Tin, Antony and Brewer, Chris M and Aushev, Vasily N and Fungtammasan, Arkarachai and Palsuledesai, Charuta C and Ortiz, J Bryce and Jurdi, Adham and Liu, Minetta C and Ghobrial, R Mark and He, Aiwu Ruth},
  title = {Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00934}
}
Kostenlos starten →